62015-79-6

Usage

InChI:InChI=1S/C10H9BrO2/c1-13-7-3-2-6-4-9(11)10(12)8(6)5-7/h2-3,5,9H,4H2,1H3

Upstream product

• 13623-25-1 6-methoxy-2,3-dihydro-1H-inden-1-one 

Relevant academic research and scientific papers

Visibly Emitting Thiazolyl-Uridine Analogues as Promising Fluorescent Probes

Microenvironment-sensitive fluorescent (ESF) nucleosides are powerful tools for nucleic acid research. The new 5-substituted uridine analogues are synthesized, which comprise a 4H-cyclopenta[d]thiazole ring obtained by the Hantzsch synthesis reaction of 5-thioamide-uridine with aromatic α-bromocarbonyl compounds. The emission maximum of new compounds is in the visible region. They exhibit strong solvent- A nd pH-dependent fluorescent properties, indicating their promising ability to be fluorescent probes.

PPh3·HBr-DMSO: A Reagent System for Diverse Chemoselective Transformations

The broad applicability of the hitherto unexplored reagent combination PPh3·HBr-DMSO is exemplified with multiple highly diverse one-step transformations to synthetically useful building blocks, such as flavones, 4H-thiochromen-4-ones, α-hydroxy ketones, 1,4-naphthoquinones (including vitamin K3), 2-bromo-3-substituted-1H-1-indenones, 2-methylthio-1H-1-indenones, 3-butyne-1,2-dione, and 4-pentene-2,3-diones. The simple and mild reaction conditions make the reagent superior in terms of yield and substrate scope in comparison with the existing alternatives.

INDANE COMPOUNDS

This invention provides new indane compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1H4) FXR is a member of the nuclear receptor class of ligand-activate transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome

Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives

In our efforts to discover more potent and lasting NHE1 inhibitors, we designed and synthesized a series of substituted indan-1-ylidene aminoguanidine derivatives (5). NHE1 inhibitory activity of twenty-one compounds 5 was evaluated in a rat platelet swelling assay. It is found that most of the tested compounds possess NHE1 inhibitory effects. 2-(5-methoxybenzimidazol-2-ylthio)-5-chloro-2,3-dihydroinden-1-ylidene aminoguanidine hydrobromide (5m) proved to be sixty-nine times more potent than cariporide. Furthermore, when tested in vivo, compound 5m also displayed superior cardioprotective effects against SD rat myocardial ischemic-reperfusion injury over those of cariporide.

Improvement in the selectivity and metabolic stability of the serotonin 5-HT1A ligand, S 15535: A series of cis- and trans-2-(arylcycloalkylamine) 1-indanols

S 15535 (1) displays a distinctive profile of agonist and antagonist (weak partial agonist) activity at pre- and postsynaptic 5-HT1A receptors, respectively. It has proven to be active in several models predictive of anxiolytic, antidepressant,

Indanol compounds

A compound of formula (I): STR1 wherein R1, R2, R3, R4, X-Y, A, Z and Z' are as defined in the description, in the form of the cis or trans isomers each in racemic or optically active form, and acid addition salts thereof, and medicinal products containing the same are useful in the treatment of diseases of the central nervous system or of manifestations of pain.

The Synthesis and Chemistry of 4-Aza-azulene

4-Aza-azulene and its 5-bromo and 6-methoxy derivatives have been efficiently synthesized by spray pyrolysis of 2-halogenoindan-1-yl azidoformates at 300 deg C and 1-2 mm pressure of nitrogen.Bromination of 4-aza-azulene gives 1-bromo, 3-bromo, and 1,3-di